GLG News by Physicians who Treat Rosacea (US)
Request a free trial
November 24, 2008Filler Warnings- Are They Necessary?
Analysis of: FDA Faults Wrinkle Fillers Over Warnings | online.wsj.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that it discusses a rare but known side effect of filler injections- reactions to these agents. These reactions include allergies, infections, etc. The incidence is low- approximately 1000 cases out of 1.5 million injections. The majority of these reactions were not serious....
August 27, 2008
A rough in the diamond
Analysis of: FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta | www.fda.gov
Author: GLG Expert Contributor
Analysis of: FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta | www.fda.gov
Author: GLG Expert Contributor
If truly an association, this will alter the use of this drug.
August 1, 2008Will access to dermatology care suffer with increased cosmetic procedures ?
Analysis of: As Doctors Cater to Looks, Skin Patients Wait | www.nytimes.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that it describes a growing trend among dermatologists to offer a higher level of "customer service" for their cash paying cosmetic patients. This has contributed in a small way to the long waits for non cosmetic dermatology patients to be able to see a dermatologist....
July 28, 2008
Onglyza - ? engagement ring for Astra Zeneca and Bristol-Myers Squibb
Analysis of: AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes | www.astrazeneca.com
Author: GLG Expert Contributor
Analysis of: AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes | www.astrazeneca.com
Author: GLG Expert Contributor
DDP4 inhibitor class fairly new. Another arrow in the theraputic quiver
July 18, 2008
Fractures from Fosamax???
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com
Author: GLG Expert Contributor
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com
Author: GLG Expert Contributor
Patients may ask about this. Haven't heard anyone yet.
July 18, 2008Will prescription drug spending decreases affect dermatology?
Analysis of: Patients Curb Prescription Spending | online.wsj.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that it describes a worrying trend for branded pharmaceutical companies. As copays for branded products go up and the patients economic status worsens, the use of these drugs will fall. This may be especially true for medications in dermatology, where the perceived...
July 7, 2008Protopic use can prevent relapse
Analysis of: Intermittent tacrolimus Ointment therapy Helps Prevent Relapse Of Stabilized Atpoic Dermatitis | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that it confirms a commonly used method in clinical dermatology practice. Namely that of using Protopic for longer term maintenance to prevent flares, and to act as a topical steroid sparing agent. This has been done since the introduction of Protopic, and among dermatologists...
July 7, 2008New uses for old meds- benefit or drawback?
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important because it describes a growing concern that is not well known to the investment community or the public. Due to increased pressure from the generic companies, the FDA, and the public many companies are finding new uses for older medications. This is very true in dermatology...
July 2, 2008Evolence Approval- what effect will it have on the filler market
Analysis of: FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler | www.investor.jnj.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important because it outlines the rationale and benefits of the new collagen based filler from Ortho-Neutrogena/ Johnson and Johnson. This filler appears to last at least 6 months, and does not require pre testing as other collagen based fillers have needed in the past. The fact that...
June 27, 2008Adolesecnt acne treatable
Analysis of: What Skin Care Routines and Treatments Are Effective for Adolescent Acne? | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that, for the most part , it describes a basic therapeutic regimen for adolescent acne patients. The only error is describing the inflamed lesions as "infections." Acne is predominantly an inflammatory condition, not an infectious one, though a bacteria is involved...
Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 94
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008

